Mario Boccadoro mostly deals with Multiple myeloma, Surgery, Internal medicine, Bortezomib and Transplantation. His studies deal with areas such as Autologous transplantation and Chemotherapy as well as Multiple myeloma. His studies in Surgery integrate themes in fields like Thalidomide, Dexamethasone and Hazard ratio.
His Internal medicine research integrates issues from Gastroenterology and Oncology. Mario Boccadoro interconnects Proteasome inhibitor, Urology, Survival rate and Adverse effect, Pharmacology in the investigation of issues within Bortezomib. In his study, which falls under the umbrella issue of Transplantation, Risk factor is strongly linked to Survival analysis.
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Surgery and Transplantation. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. His research in Multiple myeloma tackles topics such as Bone marrow which are related to areas like Cancer research.
His research in Oncology intersects with topics in Hematology, Clinical trial, Carfilzomib and Daratumumab. His Lenalidomide study combines topics in areas such as Maintenance therapy and Autologous stem-cell transplantation. The Thalidomide study combines topics in areas such as Adverse effect, Pharmacology and Salvage therapy.
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Newly diagnosed and Clinical trial. His work carried out in the field of Multiple myeloma brings together such families of science as Intensive care medicine, Maintenance therapy, Transplantation and Minimal residual disease. Lenalidomide, Dexamethasone, Carfilzomib, Bortezomib and Hematology are the core of his Internal medicine study.
His Bortezomib study integrates concerns from other disciplines, such as Thalidomide and Melphalan. The concepts of his Oncology study are interwoven with issues in Ixazomib, Relapsed refractory, Randomized controlled trial and Pomalidomide. In his study, Toxicity is strongly linked to Gastroenterology, which falls under the umbrella field of Newly diagnosed.
Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Clinical trial are his primary areas of study. His Multiple myeloma research is multidisciplinary, incorporating elements of Intensive care medicine and Minimal residual disease. His study in Oncology is interdisciplinary in nature, drawing from both Cell therapy and MRD Negativity.
His biological study spans a wide range of topics, including Treatment goals, Chimeric antigen receptor, Progression-free survival and Bone marrow. Mario Boccadoro focuses mostly in the field of Bortezomib, narrowing it down to matters related to Transplantation and, in some cases, Polypharmacy and Watchful waiting. Mario Boccadoro works mostly in the field of Hazard ratio, limiting it down to topics relating to Regimen and, in certain cases, Thalidomide, Phases of clinical research and Intention-to-treat analysis, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli.
Journal of Clinical Oncology (2010)
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
Michele Cavo;Lucia Pantani;Maria Teresa Petrucci;Francesca Patriarca.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
Antonio Palumbo;Sara Bringhen;Maria Teresa Petrucci;Pellegrino Musto.
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo;Thierry Facon;Pieter Sonneveld;Joan Bladè.
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Michele Cavo;S. Vincent Rajkumar;Antonio Palumbo;Philippe Moreau.
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;Edward Stadtmauer.
British Journal of Haematology (2009)
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo;Michele Cavo;Sara Bringhen;Elena Zamagni.
Journal of Clinical Oncology (2011)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto;Gloria Pagliano;Simone Ferrero;Federica Cavallo.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: